Sodium-glucose-co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study

Chris Sainsbury; Jingya Wang; Krishna Gokhale; Dionisio  Acosta-Mena; Samir  Dhalla; Nathan  Byne; Joht Chandan; Astha Anand; Jennifer Cooper; Kelvin Okoth; Anuradhaa Subramanian; Mansoor Bangnash; Thomas Taverner; Wasim Hanif; Sandip Ghosh; Parth Narendran; KK Cheng; Tom Marshall; Georgios Gkoutos; Konstantinos Toulis; G Neil Thomas; Abd Tahrani; Nicola Adderley; Shamil Haroon; Krishnarajah Nirantharakumar

doi:10.1111/dom.14203

Sodium-glucose-co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study

Chris Sainsbury, Jingya Wang, Krishna Gokhale, Dionisio Acosta-Mena , Samir Dhalla , Nathan Byne , Joht Chandan, Astha Anand, Jennifer Cooper, Kelvin Okoth, Anuradhaa Subramanian, Mansoor Bangnash, Thomas Taverner, Wasim Hanif, Sandip Ghosh, Parth Narendran, KK Cheng, Tom Marshall, Georgios Gkoutos, Konstantinos ToulisG Neil Thomas, Abd Tahrani, Nicola Adderley, Shamil Haroon, Krishnarajah Nirantharakumar

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

200 Downloads (Pure)

Abstract

Sodium/glucose co-transporter-2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVID-19, when compared with an active comparator.
We performed a propensity score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2i (n=9,948) and a comparator group prescribed dipeptyl-peptidase 4 inhibitors (DPP4i; n=14,917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2i and 24.7/1000 person-years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.

Original language	English
Pages (from-to)	263-269
Journal	Diabetes, obesity & metabolism
Volume	23
Issue number	1
Early online date	29 Sept 2020
DOIs	https://doi.org/10.1111/dom.14203
Publication status	E-pub ahead of print - 29 Sept 2020

Keywords

DPP‐4 inhibitor
SGLT2 inhibitor
antidiabetic drug
pharmaco‐epidemiology
type 2 diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dom.14203Licence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Sainsbury_et_al_2020_Sodium‐glucose_co‐transporter‐2_inhibitors_Diabetes_Obesity_and_MetabolismFinal published version, 622 KBLicence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Cite this

Sainsbury, C., Wang, J., Gokhale, K., Acosta-Mena , D., Dhalla , S., Byne , N., Chandan, J., Anand, A., Cooper, J., Okoth, K., Subramanian, A., Bangnash, M., Taverner, T., Hanif, W., Ghosh, S., Narendran, P., Cheng, KK., Marshall, T., Gkoutos, G., ... Nirantharakumar, K. (2020). Sodium-glucose-co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study. Diabetes, obesity & metabolism, 23(1), 263-269. Advance online publication. https://doi.org/10.1111/dom.14203

@article{3426a4f949274351bc9890aecf317338,

title = "Sodium-glucose-co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study",

abstract = "Sodium/glucose co-transporter-2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVID-19, when compared with an active comparator.We performed a propensity score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2i (n=9,948) and a comparator group prescribed dipeptyl-peptidase 4 inhibitors (DPP4i; n=14,917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2i and 24.7/1000 person-years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.",

keywords = "DPP‐4 inhibitor, SGLT2 inhibitor, antidiabetic drug, pharmaco‐epidemiology, type 2 diabetes",

author = "Chris Sainsbury and Jingya Wang and Krishna Gokhale and Dionisio Acosta-Mena and Samir Dhalla and Nathan Byne and Joht Chandan and Astha Anand and Jennifer Cooper and Kelvin Okoth and Anuradhaa Subramanian and Mansoor Bangnash and Thomas Taverner and Wasim Hanif and Sandip Ghosh and Parth Narendran and KK Cheng and Tom Marshall and Georgios Gkoutos and Konstantinos Toulis and Thomas, {G Neil} and Abd Tahrani and Nicola Adderley and Shamil Haroon and Krishnarajah Nirantharakumar",

year = "2020",

month = sep,

day = "29",

doi = "10.1111/dom.14203",

language = "English",

volume = "23",

pages = "263--269",

journal = "Diabetes, obesity & metabolism",

issn = "1462-8902",

publisher = "Wiley",

number = "1",

}

Sainsbury, C, Wang, J , Gokhale, K, Acosta-Mena , D, Dhalla , S, Byne , N, Chandan, J, Anand, A, Cooper, J , Okoth, K , Subramanian, A, Bangnash, M, Taverner, T, Hanif, W, Ghosh, S, Narendran, P , Cheng, KK , Marshall, T , Gkoutos, G, Toulis, K, Thomas, GN , Tahrani, A , Adderley, N , Haroon, S & Nirantharakumar, K 2020, 'Sodium-glucose-co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study', Diabetes, obesity & metabolism, vol. 23, no. 1, pp. 263-269. https://doi.org/10.1111/dom.14203

TY - JOUR

T1 - Sodium-glucose-co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study

AU - Sainsbury, Chris

AU - Wang, Jingya

AU - Gokhale, Krishna

AU - Acosta-Mena , Dionisio

AU - Dhalla , Samir

AU - Byne , Nathan

AU - Chandan, Joht

AU - Anand, Astha

AU - Cooper, Jennifer

AU - Okoth, Kelvin

AU - Subramanian, Anuradhaa

AU - Bangnash, Mansoor

AU - Taverner, Thomas

AU - Hanif, Wasim

AU - Ghosh, Sandip

AU - Narendran, Parth

AU - Cheng, KK

AU - Marshall, Tom

AU - Gkoutos, Georgios

AU - Toulis, Konstantinos

AU - Thomas, G Neil

AU - Tahrani, Abd

AU - Adderley, Nicola

AU - Haroon, Shamil

AU - Nirantharakumar, Krishnarajah

PY - 2020/9/29

Y1 - 2020/9/29

N2 - Sodium/glucose co-transporter-2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVID-19, when compared with an active comparator.We performed a propensity score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2i (n=9,948) and a comparator group prescribed dipeptyl-peptidase 4 inhibitors (DPP4i; n=14,917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2i and 24.7/1000 person-years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.

AB - Sodium/glucose co-transporter-2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVID-19, when compared with an active comparator.We performed a propensity score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2i (n=9,948) and a comparator group prescribed dipeptyl-peptidase 4 inhibitors (DPP4i; n=14,917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2i and 24.7/1000 person-years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.

KW - DPP‐4 inhibitor

KW - SGLT2 inhibitor

KW - antidiabetic drug

KW - pharmaco‐epidemiology

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85092669529&partnerID=8YFLogxK

U2 - 10.1111/dom.14203

DO - 10.1111/dom.14203

M3 - Article

C2 - 32991065

SN - 1462-8902

VL - 23

SP - 263

EP - 269

JO - Diabetes, obesity & metabolism

JF - Diabetes, obesity & metabolism

IS - 1

ER -

Sodium-glucose-co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this